Alvotech (ALVO) Cash from Investing Activities (2022 - 2026)
Alvotech (ALVO) posted Cash from Investing Activities of -$46.2 million for Q1 2026, down 193.0% on a QoQ basis from -$15.8 million in Q4 2025, and down 126.5% year-over-year from $174.3 million in Q1 2025.
Alvotech (ALVO) Cash from Investing Activities (2022 - 2026) Analysis & Trends
Alvotech's Cash from Investing Activities history runs 5 years deep, the most recent figure standing at -$46.2 million for Q1 2026.
- Quarterly Cash from Investing Activities fell 126.5% year-over-year to -$46.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$130.0 million (down 450.93% YoY) and the FY2025 annual result came in at -$104.2 million, down 452.34% from the prior year.
- Cash from Investing Activities was -$46.2 million for Q1 2026 at Alvotech, down from -$15.8 million in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $22.8 million in Q3 2024 and bottomed at -$63.5 million in Q4 2022.
- A 5-year average of -$22.5 million and a median of -$18.9 million in 2024 frame the typical range for Cash from Investing Activities.
- Annual changes were most pronounced in 2024 — Cash from Investing Activities jumped 74.92% — and 2025, when it slumped 486.06%.
- Alvotech's Cash from Investing Activities stood at -$63.5 million in 2022, then grew by 27.07% to -$46.3 million in 2023, then surged by 59.28% to -$18.9 million in 2024, then climbed by 16.44% to -$15.8 million in 2025, then slumped by 193.0% to -$46.2 million in 2026.
- Business Quant data shows ALVO's Cash from Investing Activities at -$46.2 million in Q1 2026, -$15.8 million in Q4 2025, and -$39.5 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 229.00 Mn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | -87.00 Mn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | -369.95 Mn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 743.70 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | 277.40 Mn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | -506.20 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | -60.00 Mn |
| 10 | Alvotech | 907.91 Mn | 907.91 Mn | 5.09 Mn | -46.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -46.20 Mn |
| Mar 31, 2026 | -46.20 Mn |
| Dec 31, 2025 | -15.77 Mn |
| Dec 31, 2025 | -15.77 Mn |
| Sep 30, 2025 | -39.45 Mn |
| Sep 30, 2025 | -39.45 Mn |
| Jun 30, 2025 | -28.60 Mn |
| Jun 30, 2025 | -28.60 Mn |
| Mar 31, 2025 | -20.40 Mn |
| Mar 31, 2025 | -20.40 Mn |
| Dec 31, 2024 | -18.87 Mn |
| Dec 31, 2024 | -18.87 Mn |
| Sep 30, 2024 | 22.75 Mn |
| Sep 30, 2024 | 22.75 Mn |
| Jun 30, 2024 | -7.09 Mn |
| Jun 30, 2024 | -7.09 Mn |
| Mar 31, 2024 | -3.48 Mn |
| Mar 31, 2024 | -3.48 Mn |
| Dec 31, 2023 | -46.34 Mn |
| Dec 31, 2023 | -46.34 Mn |